Personal Genome Diagnostics and PathGroup Enter Co-Development Agreement to Accelerate the Availability of Comprehensive Genomic Profiling with TMB

BALTIMORE – (Monday, January 7, 2019) – Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, and PathGroup, a premier provider of anatomic, clinical and molecular laboratory services, announced today that they have entered into a co-development agreement for the PGDx elio™ tissue complete assay.

Click Here to read the press release.